Seeking Alpha EN

AC Immune GAAP EPS of -CHF0.70, revenue of CHF3.57M

Mar 13, 2026 &03091313202631; 11:09 UTC seekingalpha.com Trending 2/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -65/100

Moderate impact Short-term (days)

WHAT THIS MEANS

AC Immune reported a significant loss with GAAP EPS of -CHF0.70 and minimal revenue of CHF3.57M, indicating the company is in early-stage development with substantial cash burn. This reflects typical biotech pre-commercialization metrics with no meaningful product revenue generation.

AI CONFIDENCE

75% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

ACIM

ACIMStock

Expected to decline

Negative EPS and minimal revenue indicate ongoing losses and lack of commercial traction; typical biotech burn rate concerns

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Avoid or reduce exposure to ACIM unless you have conviction in pipeline assets and can tolerate significant downside risk. Monitor upcoming clinical trial results and funding announcements as key catalysts for potential recovery.

KEY SIGNALS

Negative earnings per share (-CHF0.70)Minimal revenue generation (CHF3.57M)High cash burn rate typical of pre-clinical/early-stage biotechNo near-term profitability visibleDependency on pipeline success and funding

SECTORS INVOLVED

BiotechnologyHealthcarePharmaceuticals

Analysis generated on Mar 16, 2026 at 14:49 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

AC Immune GAAP EPS of -CHF0.70, revenue of CHF3.57M

RELATED INTELLIGENCE